Tumor necrosis factor alpha–Nuclear factor kappa B signaling axis (TNF-α–NF-κB axis) (TNF-α–NF-κB axis)

The Tumor necrosis factor alpha–Nuclear factor kappa B (TNF-α–NF-κB) signaling axis is a fundamental proinflammatory pathway that coordinates the body's response to injury and infection (Source: PubMed, PMID: 30233453). The axis is activated when the cytokine TNF-α binds to its cognate receptors, primarily TNFR1, triggering a complex intracellular signaling cascade that culminates in the activation of the IκB kinase (IKK) complex (Source: NIH, StatPearls). This complex phosphorylates IκB proteins, leading to their ubiquitin-mediated proteasomal degradation, which releases the transcription factor NF-κB to translocate into the nucleus (Source: UniProt). Once in the nucleus, NF-κB promotes the expression of a wide array of genes involved in inflammation, cell survival, and the immune response (Source: Nature Reviews Immunology). Chronic dysregulation of this axis is a primary driver of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis, and it also plays a significant role in promoting tumor cell survival and chemoresistance in various cancers (Source: PubMed, PMID: 24445666). Pharmacological inhibitors, particularly TNF-α antagonists like adalimumab and infliximab, are widely used to treat these conditions by interrupting the signaling flow, though they require careful monitoring due to risks of immunosuppression and serious infection (Source: FDA, Mayo Clinic).

Other names

TNF-NFkB pathwayTNF-alpha/NF-kappaB signaling pathwayTumor necrosis factor-mediated NF-kappaB activationTNF-TNFR-NFkB axis

Therapeutic modulation of this axis is primarily achieved by neutralizing the ligand (TNF-alpha) with monoclonal antibodies or decoy receptors to prevent binding to TNFR1/2, or by inhibiting downstream components such as the proteasome to prevent the degradation of IkappaB, thereby sequestering NF-kappaB in the cytoplasm and preventing its transcriptional activity.